Trial · NCT05895838
The Danish Out-of-Hospital Cardiac Arrest Study
NCT05895838, Phase 3, Active not recruiting, Christian Hassager
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. The Danish Out-of-Hospital Cardiac Arrest Study. Trials, record NCT05895838. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05895838
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Danish Out-of-Hospital Cardiac Arrest Study
- NCT number
- NCT05895838
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 1,000 participants, estimated
- Lead sponsor
- Christian Hassager
- Conditions
- Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
- Interventions
- Dexamethasone, Backrest elevation, Early wakeup call, Olanzapine
- First posted
- 2023-06-09
- Last updated
- 2026-11-05
- Other registries' IDs
- eudract:2021-005876-21
Source ClinicalTrials.gov
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Steroid intervention primary endpoint: All-cause mortality | 90 days | Number of patients dying from all causes |
| Primary | Back rest position intervention primary endpoint: All-cause mortality | 90 days | Number of patients dying from all causes |
| Primary | Early wakeup and extubation intervention primary endpoint: Days alive outside hospital | 30 days | Counted as days alive outside of hospital after discharge |
| Primary | Olanzapine intervention primary endpoint: Days alive outside hospital | 30 days | Counted as days alive outside of hospital after discharge |
| Secondary | Steroid intervention: Number of patients with one or more serious adverse reactions to dexamethasone in the ICU | Patients will be monitored for the occurrence of an adverse event for 30 days after randomization or until hospital discharge if this occurs later than 30 days and will not be followed for adverse event reporting after this. | Number of patients with one or more serious adverse reactions to dexamethasone in the ICU |
| Secondary | Steroid intervention: Days alive outside hospital within 30 days | 30 days | Days alive outside hospital within 30 days |
| Secondary | Steroid intervention: Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest | 3-6 months | Cerebral Performance Category (CPC) and Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest (conducted either through physical attendance or telephone interview according to participant preference) |
| Secondary | Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest | 3-6 months | Modified Rankin Scale (mRS) at follow-up 3-6 months after cardiac arrest (conducted either through physical attendance or telephone interview according to participant preference) |
| Secondary | Steorid intervention: Serum Neuron Specific Enolase (NSE) at 48-72 hours | 48-72 hours | Serum Neuron Specific Enolase (NSE) at 48-72 hours |
| Secondary | Steroid intervention: Markers of inflammation (high-sensitivity C reactive protein) | 0-72 hours | Markers of inflammation; high-sensitivity C reactive protein. platelet-, leukocyte- and differential count daily during the initial 72 hours |
1 to 10 of 31Source ClinicalTrials.gov
See all 31 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05895838
GET https://conductscience.org/api/trials/v1/NCT05895838/registered?page=2